Analyst firms · Morgan Stanley · LEGN
Morgan Stanley LEGN price target and rating history
Legend Biotech Corporation (LEGN) · Health Care
Morgan Stanley rates Legend Biotech Corporation (LEGN) Overweight with a $55 price target, as of its latest action on Mar 7, 2022. It has published 4 rating actions on LEGN since October 2021, including 1 upgrade and 1 downgrade. Across 4 firms with a LEGN price target in the last 12 months, the median target is $26.
- Current rating
- Overweight
- Price target
- $55
- Median target, all firms
- $26
- Actions on LEGN
- 4
Morgan Stanley price target on LEGN
Every Morgan Stanley rating on LEGN
- Mar 7, 2022
- Jan 31, 2022
- Jan 6, 2022
- Oct 12, 2021
How other firms rate LEGN
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Evercore ISI | In-line | Nov 13, 2026 | |
| Oppenheimer | Perform | $75 | Aug 12, 2026 |
| UBS | Neutral | $28 | Jul 24, 2026 |
| Rothschild & Co Redburn | Neutral | $24 | Feb 12, 2026 |
| TD Cowen | Hold | $21 | Jan 22, 2026 |
Questions about Morgan Stanley and LEGN
- What is Morgan Stanley's price target for LEGN?
- Morgan Stanley's latest stated price target for Legend Biotech Corporation (LEGN) is $55, from its action on Mar 7, 2022.
- What is Morgan Stanley's rating on LEGN?
- Morgan Stanley rates LEGN Overweight, a bullish rating, as of Mar 7, 2022.
- When did Morgan Stanley last change its view on LEGN?
- On Mar 7, 2022, Morgan Stanley raises its price target to $55 from $51, keeps Overweight.
- How does Morgan Stanley's LEGN target compare with other analysts?
- Across 4 firms with a LEGN price target in the last 12 months, the median target is $26.
All Morgan Stanley ratingsLEGN news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.